Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01359657 | Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | PHASE1 | COMPLETED | 46 | — | — | Sep 1, 2011 | Mar 1, 2016 | Mar 16, 2016 | 4 | United States |
| Arm | Type | Description |
|---|---|---|
| Arm A: Anti-CXCR4 (BMS-936564)+Lenalidomide+Dexamethasone | EXPERIMENTAL | - |
| Arm B: Anti-CXCR4 (BMS-936564)+Bortezomib+Dexamethasone | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Anti-CXCR4 (BMS-936564) | BIOLOGICAL | Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles |
| Lenalidomide | BIOLOGICAL | Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21 |
| Dexamethasone | BIOLOGICAL | Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles |
| Bortezomib | BIOLOGICAL | Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11 |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: * Subjects must have confirmed diagnosis of multiple myeloma with measurable disease Excluded are subjects with only plasmacytomas, plasma cell leukemia, or non-secretory myel...